Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ariel Perez

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
The American Journal of Case Reports|January 21, 2020
T Cell Primary Effusion Lymphoma in an HIV-Negative Man with Liver CirrhosisJacqueline Kropf, Mina Gerges, Ariel Perez Perez, et al.
Transplantation and Cellular Therapy|June 2, 2021
Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell LymphomaAlbert Cortes-Bullich, Ariel Perez, Christina Bachmeier, et al.
Transplantation and Cellular Therapy|April 2, 2021
Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-AnalysisFarhad Khimani, Mudit Dutta, Rawan Faramand, et al.
Journal for Immunotherapy of Cancer|May 17, 2022
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCLKai Rejeski, Ariel Perez, Gloria Iacoboni, et al.
Transplantation and Cellular Therapy|July 30, 2021
Increased Infections and Delayed CD4<sup>+</sup> T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic TransplantationFarhad Khimani, Peter Ranspach, Hany Elmariah, et al.
Blood|June 24, 2021
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphomaKai Rejeski, Ariel Perez, Pierre Sesques, et al.
Science Advances|September 22, 2023
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansionKai Rejeski, Ariel Perez, Gloria Iacoboni, et al.
Transplantation and Cellular Therapy|September 29, 2022
Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including DialysisAnthony C Wood, Ariel Perez Perez, Brian Arciola, et al.
Hemasphere|July 14, 2023
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product UseVeit Bücklein, Ariel Perez, Kai Rejeski, et al.
Blood Advances|October 14, 2021
A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host diseaseAleksandr Lazaryan, Stephanie Lee, Mukta Arora, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
The American Journal of Case Reports|January 21, 2020
T Cell Primary Effusion Lymphoma in an HIV-Negative Man with Liver CirrhosisJacqueline Kropf, Mina Gerges, Ariel Perez Perez, et al.
Transplantation and Cellular Therapy|June 2, 2021
Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell LymphomaAlbert Cortes-Bullich, Ariel Perez, Christina Bachmeier, et al.
Transplantation and Cellular Therapy|April 2, 2021
Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-AnalysisFarhad Khimani, Mudit Dutta, Rawan Faramand, et al.
Journal for Immunotherapy of Cancer|May 17, 2022
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCLKai Rejeski, Ariel Perez, Gloria Iacoboni, et al.
Transplantation and Cellular Therapy|July 30, 2021
Increased Infections and Delayed CD4<sup>+</sup> T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic TransplantationFarhad Khimani, Peter Ranspach, Hany Elmariah, et al.
Blood|June 24, 2021
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphomaKai Rejeski, Ariel Perez, Pierre Sesques, et al.
Science Advances|September 22, 2023
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansionKai Rejeski, Ariel Perez, Gloria Iacoboni, et al.
Transplantation and Cellular Therapy|September 29, 2022
Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including DialysisAnthony C Wood, Ariel Perez Perez, Brian Arciola, et al.
Hemasphere|July 14, 2023
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product UseVeit Bücklein, Ariel Perez, Kai Rejeski, et al.
Blood Advances|October 14, 2021
A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host diseaseAleksandr Lazaryan, Stephanie Lee, Mukta Arora, et al.
Pageof 2